Compare Inovio Pharmaceuticals Inc (INO) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while TotalEnergies SE trades at $82.51 (market cap $179.99B). The key difference: TotalEnergies SE is far larger — about 2016.2× Inovio Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 5.22% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | TTE | |
|---|---|---|
Market Cap | $89.27M | $179.99B |
Sector | Health | Energy |
52-Week High | $2.87 | $93.60 |
52-Week Low | $1.05 | $57.39 |
Enterprise Value | $60.28M | $214.14B |
Dividend Yield | — | 5.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
TotalEnergies (TTE) trades at $81.23, down 0.2% on the day, with a bullish technical signal supported by moving averages. The company reported a Q1 2026 EPS beat of $2.45 versus $2.22 expected, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Valuation remains attractive with a P/E of 12.08 and P/S of 0.97. Recent news highlights strategic divestments in solar and new LNG shipments to Asia, reflecting a focus on profitable growth areas.
The outlook is positive with a consensus price target of $100, implying 23% upside, supported by 57.6% analyst buy ratings. Risks include ongoing revenue pressure, geopolitical exposure in the Middle East, and regulatory climate mandates. Cash flow stability and shareholder returns via dividends provide a cushion, but execution on production growth and cost management is critical for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
